S&P revises AmeriPath to stable

Standard & Poor's said it revised its outlook on leading anatomic pathology laboratory AmeriPath Inc. to stable from positive and affirmed its B+ corporate credit and senior secured debt ratings and its B- subordinated debt rating.

S&P said the outlook revision reflects slower-than-expected improvement in the company's operations and credit profile.

The speculative-grade ratings reflect AmeriPath's participation in the U.S. market for anatomic pathology services, a niche segment of the diagnostic services market that is subject to reimbursement risks and competitive uncertainties.

The ratings also indicate management's aggressive financial policy, evidenced by its acquisition of more than 50 anatomic pathology businesses since its formation in 1996. The company performed a leveraged buyout in 2003.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.